https://glp1tirzepatidereview.com/news/fda-503b-bulks-exclusion-proposal/GLP-1 Tirzepatide Reviewen2026-07-24FDA Proposes Permanent Exclusion of Semaglutide, Tirzepatide and Liraglutide From the 503B Bulks List https://glp1tirzepatidereview.com/news/fda-comment-period-extension-503b/GLP-1 Tirzepatide Reviewen2026-07-24Comment Period on the GLP-1 Bulks Proposal Extended to 30 July https://glp1tirzepatidereview.com/news/fda-25-warning-letters-june-2026/GLP-1 Tirzepatide Reviewen2026-07-24FDA Sends 25 More Warning Letters Over Compounded GLP-1 Marketing Claims https://glp1tirzepatidereview.com/news/foundayo-orforglipron-fda-approval/GLP-1 Tirzepatide Reviewen2026-07-24FDA Approves Foundayo (Orforglipron), the First Small-Molecule Oral GLP-1 for Weight Loss https://glp1tirzepatidereview.com/news/wegovy-pill-oral-semaglutide-approval/GLP-1 Tirzepatide Reviewen2026-07-24FDA Approves the Wegovy Pill: Oral Semaglutide 25 mg for Weight Management https://glp1tirzepatidereview.com/news/step-up-semaglutide-7-2mg/GLP-1 Tirzepatide Reviewen2026-07-24STEP UP: Semaglutide 7.2 mg Reports 20.7% Weight Loss, Narrowing the Gap With Tirzepatide https://glp1tirzepatidereview.com/news/medicare-glp1-bridge-launches/GLP-1 Tirzepatide Reviewen2026-07-24Medicare GLP-1 Bridge Opens: $50 a Month for Eligible Part D Enrollees https://glp1tirzepatidereview.com/news/balance-model-part-d-delayed/GLP-1 Tirzepatide Reviewen2026-07-24CMS Delays the BALANCE Model Indefinitely and Extends the GLP-1 Bridge Instead https://glp1tirzepatidereview.com/news/trumprx-launch-direct-pricing/GLP-1 Tirzepatide Reviewen2026-07-24TrumpRx Launches Direct GLP-1 Pricing, Undercutting List Prices by Up to Nine Times https://glp1tirzepatidereview.com/news/novocare-wegovy-price-cut/GLP-1 Tirzepatide Reviewen2026-07-24NovoCare Cuts Wegovy Self-Pay Pricing to $349 From $499 https://glp1tirzepatidereview.com/news/soul-trial-oral-semaglutide-cardiovascular/GLP-1 Tirzepatide Reviewen2026-07-24SOUL: Oral Semaglutide Cuts Major Cardiovascular Events by 14% in High-Risk Type 2 Diabetes https://glp1tirzepatidereview.com/news/evoke-alzheimers-null-result/GLP-1 Tirzepatide Reviewen2026-07-24EVOKE and EVOKE+: Oral Semaglutide Made No Difference to Alzheimer's Progression https://glp1tirzepatidereview.com/news/reimagine-2-cagrisema-diabetes/GLP-1 Tirzepatide Reviewen2026-07-24REIMAGINE 2: CagriSema Beats Semaglutide on HbA1c by 1.91 Points With 14.2% Weight Loss https://glp1tirzepatidereview.com/news/synchronize-1-visceral-liver-fat/GLP-1 Tirzepatide Reviewen2026-07-24SYNCHRONIZE-1: 16.6% Weight Loss With 34% Less Visceral Fat and 63% Less Liver Fat https://glp1tirzepatidereview.com/news/structure-therapeutics-oral-access-ii/GLP-1 Tirzepatide Reviewen2026-07-24ACCESS II: A Second Oral Small-Molecule GLP-1 Posts 16.3% Placebo-Adjusted Weight Loss https://glp1tirzepatidereview.com/news/fda-peptide-advisory-committee-july-2026/GLP-1 Tirzepatide Reviewen2026-07-24FDA Advisory Committee Reviews BPC-157, TB-500 and Five Other Peptides This Week https://glp1tirzepatidereview.com/news/generic-tirzepatide-anda-filings/GLP-1 Tirzepatide Reviewen2026-07-24Sandoz and Amneal File for Generic Tirzepatide — But Lilly's Patents Run to 2036 https://glp1tirzepatidereview.com/news/fda-february-2026-api-restriction/GLP-1 Tirzepatide Reviewen2026-07-24FDA Signals It Will Restrict GLP-1 Active Ingredients Used in Non-Approved Compounded Products https://glp1tirzepatidereview.com/news/tirzepatide-shortage-timeline-litigation/GLP-1 Tirzepatide Reviewen2026-07-24The Tirzepatide Shortage Delisting Was Not One Date — It Was a Year of Litigation https://glp1tirzepatidereview.com/news/compounded-b12-chemical-bonding-study/GLP-1 Tirzepatide Reviewen2026-07-24A 2026 Study Finds Tirzepatide and B12 Can Chemically Bond — Forming a Molecule Not in the Approved Drug https://glp1tirzepatidereview.com/news/surmount-5-published-nejm/GLP-1 Tirzepatide Reviewen2026-07-24SURMOUNT-5 Published: Tirzepatide 20.2% Against Semaglutide 13.7% in the First Head-to-Head https://glp1tirzepatidereview.com/news/summit-hfpef-results/GLP-1 Tirzepatide Reviewen2026-07-24SUMMIT: Tirzepatide Cuts Worsening Heart-Failure Events by 38% in Obesity-Related HFpEF https://glp1tirzepatidereview.com/news/surmount-1-three-year-diabetes-prevention/GLP-1 Tirzepatide Reviewen2026-07-24Three Years of Tirzepatide Markedly Reduced Progression to Type 2 Diabetes in Prediabetes https://glp1tirzepatidereview.com/news/zepbound-osa-indication/GLP-1 Tirzepatide Reviewen2026-07-24Zepbound Now Carries an Obstructive Sleep Apnoea Indication Alongside Weight Management https://glp1tirzepatidereview.com/news/gallup-glp1-use-obesity-decline/GLP-1 Tirzepatide Reviewen2026-07-24GLP-1 Use Reaches 11% of US Adults as the Obesity Rate Falls to 36.4% https://glp1tirzepatidereview.com/news/ada-2026-bimagrumab-lean-mass/GLP-1 Tirzepatide Reviewen2026-07-24ADA 2026: Adding a Myostatin Inhibitor Cut the Lean-Mass Share of Weight Loss From 21% to 7% https://glp1tirzepatidereview.com/news/ada-2026-osteoarthritis-outcomes/GLP-1 Tirzepatide Reviewen2026-07-24ADA 2026: Semaglutide Improved Knee Osteoarthritis Pain — and Tirzepatide's Extra Weight Loss Did Not Add More https://glp1tirzepatidereview.com/news/wegovy-pill-three-million-prescriptions/GLP-1 Tirzepatide Reviewen2026-07-24The Wegovy Pill Passed Three Million Prescriptions in Just Over Five Months https://glp1tirzepatidereview.com/news/semaglutide-shortage-resolved-enforcement/GLP-1 Tirzepatide Reviewen2026-07-24Semaglutide Came Off the Shortage List in February 2025 — With a May Deadline for Outsourcing Facilities https://glp1tirzepatidereview.com/news/hims-compounded-wegovy-pill-withdrawal/GLP-1 Tirzepatide Reviewen2026-07-24A Major Telehealth Platform Withdrew a Compounded Copy of the Wegovy Pill Under Legal Threat